- 1. Table of Contents (Page 1)
- 2. Basic Information (Page 2)
- 3. Packaging & Pictures (Page 3-4)
- 4. European Test & Technical Documentation Review Report (Page 5-9)
- 5. Registration on DIMDI & Declaration of Conformity (Page 10-11)
- 6. ISO Production Standards Report (Page 12-19)
- 7. Manufacturer Qualification Certificate & Export License (Page 20-22)

Disposable Medical Face Mask Inherent-Type IIR Strap-on

Brand: Inherent

Type No.: YX121 (Strap-on)

Performance standard: EN 14683:2019 + AC:2019(E) Annex B /C/D & YY/T 0969-2013, tested by TÜV Rheiland & Intertek

Production standards: ISO 10933-10:2010 & ISO 10993-5:2009, tested by CCIC

Classifications: Type IIR Strap-on (Non-

Sterile), No latex ingredients

Material: Two-layer PP Nonwoven fabric and One-

layer BFE95 Meltblown fabric (3 layers)

Mask specifications: Universal, 17,50 x 9,50 cm

Earloop design: Breathable and comfortable for prolonged w earing

Expiration date: 2 years from date of manufacturing

Packing specifications: 50 pcs. / box, 40 boxes 2000 pcs. / carton, 16 cartons / euro pallet

Carton measurements: 57 x 39 x 42 cm, G.W. 9.2 KGS.

Stock available: Rotterdam The Netherlands, Frankfurt a/m Germany and Madrid Spain















Prüfbericht-Nr.: Test Report No.:	60377902 00:	2	Auftrags-Nr. Order No.:	168264746	Seite 1 von 6 Page 1 of 6
Kunden-Referenz-Nr.: Client Reference No.:	N/A		Auftragsdatur Order date:	n: May 13, 2020	
Auftraggeber: Client:			Service Co., Ltd. Liuyang Hi-tech in	dustrial developme	ent zone, Hunan,
Prüfgegenstand: Test item:	Surgical Face	Mask (non-ster	ile)		
Bezeichnung / Typ-Nr.: Identification / Type No.:	YX011, YX12	1			
Auftrags-Inhalt: Order content:	Type test				
Prüfgrundlage: Test specification:	EN 14683:201	19+AC:2019 ex	cept for clause 5.	2.6	
Wareneingangsdatum: Date of receipt:	May 25, 2020				
Prüfmuster-Nr.: Test sample No.:	20200522				
Prüfzeitraum: Testing period:	N/A		See Attack	west Dhate decom	nentation for details.
Ort der Prüfung: Place of testing:	N/A		See Attauri	nent. Prioto docum	remauori for details.
Prüflaboratorium: Testing laboratory:	TÜV Rheinlan Co., Ltd.	d (Shenzhen)			
Prüfergebnis*: Test result*:	Pass				
geprüft von / fested by:	8		kontrolliert vo	n I reviewed by:	
Lucy	liang			Sozeled	
Jun. 02, 2020 Lucy Jian	· ·	oject Engineer	Jun. 02, 2020	Angela Chen / Dep	partment Manager
Datum Name / Stell Date Name / Post	ung	Unterschrift Signature	Datum 8	Iame / Stellung Iame / Position	Unterschrift Signature
Sonstiges / Other: - The test report considecumentation (6 page - This report is only va	sts of EN 14683 s).	3 test report incl	uding this cover p	age (6 pages) and	
Zustand des Prüfgeger Condition of the test item		nlieferung:		ständig und unbes lete and undamag	
Legende: 1 = sehr gut P(ses) = entapricht o Legend: 1 = very good	2 = get g. Prifgrundiage(n) 2 = geod	3 = betiedigent Foats = entspricht of 3 = satisfactory F(all) = falled a.m. (4 = sistreichend NIA = nicht anwendbar 4 = sufficieré NIA = not applicable	5 = mangethaft NT = richt getestet 5 = poor NT = not teated

Opplication in extinacts. This test report does not entitle to carry any test made TUV Reviewer Co., Ltd., East of Fir, Fiz. Fig., Building 1, Opton Technology Building, No. 6 Langshan No. 2 Road, Note: New York Co., Sec. 1997, 1997

	EN 14683:2019+AC: 2019 Medical face masks —
	uirements and test methods
Report Reference No:	
Date of issue	See cover page See cover page
Testing Laboratory	TÜV Rheinland (Shenzhen) Co., Ltd.
Address	F East & 2-4F, Cybio Technology Building No.1, No.16 Kejibei 2n Road, High-Tech Industrial Park North Nanshan District, 518057, Shenzhen, China
Applicant's name:	Hunan EEXI Technology & Service Co., Ltd.
Address:	No.6, North of Pingtou road, Liuyang Hi-tech industrial developmer zone. Hunan. China
Test specification:	
Standard	EN 14683:2019+AC:2019
Test procedure	Type test
Non-standard test method	N/A
Test Report Form No:	EN 14683:2019+AC:2019_A
Test Report Form Originator:	TÜV Rh (SZ)
Master TRF	2020-03
Test item description	Surgical Face Mask (non-sterile)
Trade Mark:	Inherent
Manufacturer	Same as the applicant
Model/Type reference	YX011, YX121
Classification	Type IIR

OMF-RT-330385HG Revision number: 1.0 Effective date: 2020-03-12





QMF-RT-330085HG Revision number: 1.0 Effective date: 2020-03-12 QMF-RT-330085HG Revision number: 1.0 Effective date: 2020-03-12



	EN 14683:2019+AC:20	19	
Clause	Requirement + Test	Result - Remark	Verdict
5	Requirements	7	Р
5.1	General		Р
5.1.1	Materials and construction		Р
	The medical face mask is a medical device, generally composed of a filter layer that is placed, bonded or moulded between layers of fabric.	The Surgical Face Masks are made of blank mask, nose olip and tie-on belts. The outer and inner layers of the mask are made of non-woven fabrics, and the middle layer is made of melt-blown polypropylene.	Р
	The medical face mask shall not disintegrate, split or tear during intended use.		Р
	In the selection of the filter and layer materials, attention shall be paid to cleanliness.		Р
5.1.2	Design		Р
	The medical face mask shall have a means by which it can be fitted closely over the nose, mouth and chin of the wearer and which ensures that the mask fits closely at the sides.		Р
	Medical face masks may have different shapes and constructions as well as additional features such as a face shield (to protect the wearer against splashes and droplets) with or without anti-fog function, or a nose bridge (to enhance fit by conforming to the nose contours).	With nose clip	Р
6	Marking, labelling and packaging		Р
	Annex I, §13, of the Medical Devices Directive (93/42/EEC) or Annex I, §23, of the Medical Device Regulation (EU) 2017/745 specifies the information that should be specified on the packaging in which the medical face mask is supplied.	See page 4 and attachment.	Р
	The following information shall be supplied:		Р
	a) number of this European Standard;		P
	b) type of mask (as indicated in Table 1).		Р
	EN ISO 15223-1:2016 and EN 1041:2008+A1:2013 should be considered.		Р

End of EN 14683 test report



Photo Documentation

ATTACHMENT




Figure 2 Top view of packaging box (Model: YX121)



Figure 3 Side view of packaging box (Model: YX121)











TEST REPORT



Report Ref:	GZHT02294303-S1	THIS IS TO SUPERSEDE REPORT NO. GZHT02294303 DATED Jun 03, 2020
Date Received:	May 19, 2020/May 22, 2020	Date Issued: Jun 89, 2020
Company Name: Address: Contact Name:	HUNAN EEXI TECHNOLOGY NO.6, NORTH OF PINGTOU LIUYANG HI-TECH INDUSTI DEVELOPMENT ZONE, HUN CHINA	ROAD RIAL
The Following Sample Was	Submitted And Identified By/On E	lehalf Of The Applicant As:
End Uses	: Non-Sterile Medical Face I	łask
Ratings	: Type IIR	
Sample Name	: Disposable Surgical Mask	
Size	: 17.5*9.5cm	
Colour	: Blue/white	
Standard	: EN 14683:2019+AC:2019	
Manufacturer	: HUNAN EEXI TECHNOLOG	Y & SERVICE CO., LTD
Brand Name	Inherent	
		20
Date received/ Test Star	ted : May 19, 2020/May 22, 20. : Type No.: YX121	





191. E291. E301. E401. E501. E801. E701. E801 Tec +86 20 8213 5001 Fax. +88 20 8205 9009 Postcode: 510863

intertek TEST REPORT







Room 02, 14F & Room 01, E101を201を201を401を601を601を101を201を No.7-2, Capin Room Guargatou Doesoo City, GETDO, Guargatou, China 中国厂州经过技术打发区科学城宏樹路 7 号之二集 1 一ま屋 02 祭。01 第

intertek

TEST REPORT

Summary of testing:





intertek TEST REPORT





As Per EN 14683:2019+AC:2019 Medical face masks-Requirements and test methods Annex D.

			Result (cfu/g	1		Limit
Test Item	Specimen (1)	Specimen (2)	Specimen (3)	Spedmen (4)	Spedmen (5)	(cfu/g)
Microbial cleanliness	<1#	4	3	2	1	Type IIR ≤30

This Test Item Was Conducted In Calpin Road, Guangzhou Science City, GETDD, Guangzhou, Guar Sample Received Condition: Sample In Closed Plastic Bag.



With reference to following standard:

• EN 14683:2019+AC:2019 Medical face masks – Requirements and test methods Type IIR Materials Used in The Submitted Sample Were Found To Comply With The Type IIR Requirements of EN 14683:2019+Ac;2019 with respect to Microbial Cleanliness, Bacterial Filtration Efficiency, Differential Pre-Splash Resistance Pressure tests.

Page 3 Of 7

Room 02, 1-8F & Room 01, 6101年201年301年401年801年801年801年101日801 No.7-2, Carpin Road, Guargphou Science City, GETDO, Guangphou, China 中国厂資経済技术开发区科学域安徽館 7 号之二第 7 - 8 差 02 房、01 資 101. E201, E301, E401, E501, E601, E701, E821 Tel: +88.20.8213.8001 Fax: +88.20.8206.8909 Postoide: 510863

intertek

TEST REPORT

Bacterial Filtration Efficiency (BFE)
 As Per EN 14683:2019+AC:2019 Medical face masks – Require

			Results (%)			Performance Requirement fo
Test Item	Specimen (1)	Spedmen (2)	Specimen (3)	Specimen (4)	Spedmen (5)	Medical Face Mask (%)
Bacterial Filtration Efficiency (BEE)	>99.9	99.9	99.8	99.9	99.9	Type IIR: ≥98

To Biological Aerosci: Staphylococcus aureus (ATCC 6538).

2. Testing sists: Outside of the test specimen was facing towards the challenge aerosci.

3. Test area; 260 m. Testing sists of the positive controls: 1900 CPU

6. The average plate count resists of the regative controls: < 1 CPU

7. CIV of Colony Primiting URT.

This Item Is Not Under The Testing Scope Of CNAS Accreditation
This Test Item Was Conducted In Calpin Road, Guangzhou Science City, GETDD, Guangzhou

intertek

TEST REPORT





3 Splash Resistance Pressure (ISO 22609:2004):

Remark: 1, Test was conducted by CNTAC Testing Service Co.,Ltd.(Foshan) 2.This Item Is Not Under The Testing Scope Of CNAS Accreditation

101. E201. E301. E401. E501. E501. E701. E801 Tot: +88.20 8213 9001 Fax: +88.20 8208 9309 Posicode: 510893

intertek

TEST REPORT

Result (Pa/cm²)

Remark: 1. Test was conducted by CNTAC Testing Service Co., Ltd.(Foshan, 2. This Item Is Not Under The Testing Scope Of CNAS Accreditation

intertek





To: HUNAN EEXI TECHNOLOGY & SERVICE CO LTD Attention: 協能統 Date: Jun 09, 2020

Re : Report Revision Notification
Labtest Report Number GZHT02294303 date JUN 03, 2020

Please be informed that all the content recorded in the above captioned report will be void. This captioned report is now superseded by a revised Labtest Report, Number GZHT02294303-51, issued on Jun 09, 2020.




Emica Yu

101. E281, E301. E401. E501. E601. E701. E801 Tel: +86.20 8213 9001 Pair. +86.20 8208 9009 Postgode: 510660









	Antage (au § 4 Abs. 1 Nr. 1 DMD/n Formulamammer 003009
Vertreter / Deputy (optional)	
Bezeichnung / Name	
Telefon / Phone	Telefax / Fax
E-Mail / E-mail	
£ Erstanzeige / Initial notification	
S Änderungsanzeige / Notification of change	1

		Abs. 1 Nr. 1 Dib diamummer 0030
dizinprodukt (Erstmaliges Inverkehrbringen) / Medical device (First pl	acing on the market)	
Klasse / Class		
SI		
£ I - steril / sterile		
£ I - mit Messfunktion / with measuring function		
£ I - steril und mit Messfunktion / sterile and with measuring function		
£ IIa		
dli 3		
III 2		
£ III - hergestellt unter Verwendung von Gewebe tierischen Ursprungs im (EU) Nr. 722/2012	Sinne der Verordnung	
manufactured utilising tissues of animal origin in terms of Commission	Regulation (EU) No 722/	2012
£ Aktives implantierbares Medizinprodukt / Active implantable medical de	rvice	
Aktives implantierbares Medizinprodukt - hergestellt unter Verwendung Sinne der Verordnung (EU) Nr. 722/2012	von Gewebe tierischen I	Jrsprungs in
Active implantable medical device - manufactured utilising tissues of a	nimal origin in terms of C	ommission
Regulation (EU) No 722/2012		
App (Software auf mobilen Endgeräten)	£ ja/yes	S nein / r
Nummer(n) der Bescheinigung(en) / Certificate number(s)		
Handelsname des Produktes / Trade name of the device EEXI		
Produktbezeichnung / Name of device Disposable surgical mask		
Nomenklaturcode / Nomenclature code 12-458		
Nomenklaturbezeichnung / Nomenclature term Maske, Chirurgie		
Kategoriecode / Category code 10		
Kategorie / Category Produkte zum Einmalgebrauch		
Kurzbeschreibung deutsch / German short description		
Kurzbeschreibung englisch / English short description Disposable surgical mask is intended to be used for clinical staff an	d operation room docto	ure.

-3-

-5-







Skin Sensitization Test Guinea Pig Maximization

Final Report

Article Name: Disposable medical face mask Report Number: CSTBB20030201

Method Standard: ISO 10993-10: 2010

Hunan EEXI Technology&Service Co.,Ltd. CCIC Huatongwei international inspection (Suzhou) Co., Ltd Room 101, Building G, Ruoshui Road 388, Suzhou, Jianosu, China

CCIC Huatongwei international inspection (Suzhou) Co., Ltd , Building G, Ruoshui Road 388, Suzhou, Jingsu. China, 512123 Tel: 0512-87657288 Fax: 0512-87657288 Page 1 of 11

Report No.: CSTBB20030201

Notices

- 1. Please apply for rechecking within 15 days of receiving the report if there is any objection.
 2. Any erasure or without special testing seal renders the report null and void.
 3. The report is only valid when signed by the persons who edited, checked and approved it.
 4. The report is only responsible for the set results of the tested samples.
 5. The report shall not be reproduced except in full without the written approval of the company.



Page 3 of 11

CONTENTS

(0)	ices.
b	stract
tu	dy Verification and Signature
	1.0 Purpose
	2.0 Reference
	3.0 Test and control articles
	4.0 Identification of test system.
	5.0 Animal Managment
	6.0 Equipment and reagents.
	7.0 Experiment design
	8.0 The results observed.
	9.0 Evaluation criteria
	10.0 Results of the test.
	11.0 Conclusion.
	12.0 Record
	13.0 Confidentiality Agreement

Page 2 of 11

Report No.: CSTBB20030201

Abstract

In this study, we took guinea pigs to observe the skin sensitization of the test article according to ISO 10993-10: 2010.

The test article were extracted in Constant Temperature Vibrator at 50 °C, 60 rpm for 72 h by 0.9 % Sodium Chloride Injection and Sesame Oil. Mix 30:50 (by volume) stable emulsion of Freund's complete adjuvant with selected solvent. Intradermal induction and topical induction were operated in the citipped intrascapular region of each animal. After the topical induction place was completed on day 14, all test and control animals were challenged with the test sample. The erythema and edema of the challenges its were observed to test the sensitization reposts of the test arche. According to the Maginusson and Alignams scales, the response to erythema and celema at each application site of the skin was described and scored 24 hours and 48 hours after the challenge thase.

The results showed that the guinea pigs in the negative control group (0.9 % Sodium Chloride Injection, Sesame Oil) retained a normal appearance throughout the test and showed no skin irritants. A severe skin reactions for crythema and oederna were shown in the positive control group (DKCE). While in test article group, the response of skin on testing side did not exceed that on the control side. The skin reactions for crythema and oederna were not observed in test article group. The data of each group met the acceptance criteria, and the results of this test were considered valid.

Based on the above results, it can be concluded that under the experimental conditions, the test article Disposable medical face mask has no potential skin sensitization on guinea pigs in the extraction method.

Study Verification and Signature



Protocol Number	SST2003006603
Protocol Effective Date	2020-03-13
Technical Initiation Date	2020-03-20
Technical Completion Date	2020-04-17
Final Report Completion Date	2020-04-18

1.0 Purpose
The test was designed to evaluate the potential of a test article to cause skin sensitization. The test is used as a procedure for screening of contact allergens in gaines pigs and extrapolating the results to humans, but it does not establish the actual risk of sensitization.

Biological evaluation of medical devices Part 10: Tests for irritation and skin sensitization (ISO 10993-10:

2010) Biological evaluation of medical devices-Part 12: Sample preparation and reference materials (ISO 10993-12-2012)
Biological evaluation of medical devices-Part 2: Animal welfare requirements (ISO 10993-2-2006)
3.0 Test and control articles

Groups	Test article	Negative Control Article(Polar)	Negative Control Article(Non-Polar)	Positive Control
Name	Disposable medical face mask	Sodium Chloride Injection (SC)	Sesame Oil (SO)	2, 4-Dinitrochlorobenzene (DNCB)
Manufacture	Hunan EEXI Technology&Service Co.,Ltd.	Shijiazhuang No.4 Pharmaceutical	Jiangxi xinsen natural vegetable oil co., Ltd.	TOKYO CHEMICAL INDUSTRY CO., LTD
Sterilization state	No	1		/
Size	17.5cm*9.5cm	500 ml	25 kg	25 g
Model	YX001	1	1	1
Lot Batch#	Not provided	1912121907	181120	H2UKD-DM
Test Article Material	PP non-woven, Meltblown filtration layer, earloop and nose clip	/	'	7
Physical State	Solid	Liquid	Liquid	Solid
Color	Not provided	Colorless	Light yellow	Light yellow
Package material	PE poly bag and paper box	1	ž.	i
Concentration	1	0.9 %	,	Induction Concentration: 0.5 % Challenge Concentration: 1.0 % Dissolved in ethanol
Total	Not provided	1	1	/

Page 6 of 11

Report No.: CSTBB20030201

Storage Condition	Room Tep.	Room Tep.	Room Tep.	Room Tep.
-------------------	-----------	-----------	-----------	-----------

4.0 Identification of test system

4.1 Test animal
Species: Hartley Guinea Pig (Cavia Porcellus)
Number: 30 (20 Test +10 Control)

Sex: 15 9, 15 8

Health status: Healthy, not previously used in other experimental procedures

Animal identification: Ear tag

Cages: Plastic eage
Acclimation Period: 7 days under the same conditions as for the actual test
4.2 Justification of test system

The albino guinea pig has been used historically for sensitization studies (Magnusson and Kligman, 1 970). The gainest pig is believed to be the most sensitive animal model for this type of study. DNCB is the positive control article recommended in the test instructions. To ensure the sensitivity of the experimental system, the positive control article should be verified every three months.

5.0 Animal Management

Animal Management

Animal purchaise: Work hengtai experimental animal breeding co. LTD SCXK (SU) 2015-0004

Bedding: Cornool Jiangua Xictong Pharmaceutical Bio-engineering Co., Ltd.

Feed: Guinea pigs were fed with full-price pellets Jiangua Xictong Pharmaceutical Bio-engineering Co., Ltd.

Water: Drinking water met the Stundards for Drinking Water Quality GB 5749-2006

Animal room temperature: 18-26 °C

Animal room redurive humidity: 30 %-70 %

Lights: 12 hours light/dark cycle, full-spectrum lighting

Personnel: Associates involved were appropriately qualified and trained Selection: Only healthy, previously unused animals were selected There were no known contaminants present in the feed, water, or bedding expected to interfere with the test

6.0 Equipment and reagents

Constant Temperature Vibrator (SHB007, calibration data: 2020/3/16), Autoclave (SHB026, calibration data: 2020/3/16), Electronic scale (SHB017, calibration data: 2020/3/16)

6.2 Reagents
Freund's adjuvant Complete liquid (SIGMA, Lot No: SLBR3877V), Sodium dodecyl sulfate (SDS SIGMA, Lot No: SLBL2304V)

Page 7 of 11

7.0 Experiment design

7.1 Sample preparation
The extracts of test article will be prepared according to the following steps:

Extracti

Aseptic Sampling			Extraction in sterile vessels				
Sampling Manner	Actually sampling	Ratio	Re	agent	Temperature	Time	pH
Whole	570.2 cm ²	6cm2: 1 ml	SC	95.0 ml	50 °C	22.1	5.5
Whole	570.2 cm ²	ecm-: 1 mi	SO	95.0 ml	30 °C	72 h	5.5

7.2. Intradermal induction plasted
A pair of O. Intradermal injections was made for each of the following, into each unimal, at the injection
sites (A, B and C) as shown in Figure 1 in the elipped intrascupular region.

Site A. A 50-50 (volume raiso) stable emulsion of Found's complete adjuvant mixed with the chosen solvent.

Site B: The test sample (unfilluted extract); the control animals were injected with the solvent alone.

Site C: The test sample at the concentration used at site B, emulsified in a 50-50 volume ratio stable emulsion
of Freund's complete adjuvant and the solvent (50-56; the control animals were injected with an emulsion of the

blank liquid with adjuvant.




Figure 1 Location of intradermal injection sites

7.2.2 Topical induction phaseII

2.2 special moticion phases:

The maximum concentration that can be achieved in Intradermal induction phase I did not produce initiation, imals are pretreated with 10% sodium dodecys sulfate 24(±2) hours before the topical induction application.

At 7 d after completion of the intradermal induction phase, administer test article extract by topical application.

to the intrascapular region of each animal, using a patch of area approximately 8 cm² (absorbent gauze), so as to cover the intradermal injection sites. Secure the patches with an occlusive dressing, Remove the dressings and patches after (48±2) h.

Treat the control animals similarly, using the blank liquid alone.
7.2.3 Challenge phase

Report No.: CSTBB2003201
At 14d after completion of the topical induction phase, challenge all test and control animals with the test
sample. Absorbent gazzes (2.5 cm2.5 cm) were soaked respectively with test article and control article. Apply the
test article extract and control article topically to two sites that were not treated during the induction stage. Secure
with an occlaims decessing. Remove the dressings and patches after (24x2) h.

8.0 The results observed

8.0 The results observed
The day after challenge exposure, the patch will be removed and the area cleaned gently with gauze if necessary. The site will be wiped gently with a 10.9% saline assisted gauze sponge prior to each scoring period. The challenge sites will be observed for signs of irritation and sensitization reaction, as indicated by crythema and edema. If necessary, the fur will be durved or clipped in advance for the convenience of dermal score.

Daily challenge observation scores will be recorded approximately 24, and 48 hours after patch removal in accordance with the following classification system for skin reactions:

Table 1 Magnusson and Kligman scale

Grading scale
0
1
2
3

9.0 Evaluation criteria

9.0 Evaluation criteria
Magnasson and Kligman grades of 1 or greater in the test group generally indicate sensitization, provided grades of less than 1 are seen in control animals.

If grades of 1 or greater are noted in control animals, then the reactions of test animals which exceed the most severe reaction in control animals are presumed to be due to sensitization.

If the response is equivocal, rechallenge is recommended to confirm the results from the first challenge.

The outcome of the test is presented as the frequency of positive challenge results in test and control animals.

Possible of the test is presented as the frequency of positive challenge results in test and control animals.

All animals were survived and no abnormal signs were observed during the study. Individual results of dermal scoring for the challenge appear in Table 2.

Scoring for the crainering appear in 1800 &.

11.0 Conclusion

The test article showed no evidence of causing delayed dermal contact sensitization in the guinea pig. Results and conclusions apply only to the test article tested. Any extrapolation of these data to other articles is the sponsor's

13.0 Confidentiality Agreement

Report No.: CSTBB20030201

Table 2 Guinea pig Sensitization Dermal Reactions

G	iroup	No.						nge patch d 48h later	Positive
			weigh(g)	weigh(g)	Erythema	Swelling	Erythema	Swelling	rate
		- 1	312.8	350.1	0	0	0	0	
	[2	310.8	349.8	0	0	0	0	
		3	311.7	346.8	0	0	0	0	
	[4	311.8	346.5	0	0	0	0	
	Test	5	313.5	350.2	0	0	0	0	0%
	lest	6	308.2	349.3	0	0	0	0	0%
		7	310.3	352.1	0	0	0	0	
SC		8	312.2	350.6	0	0	0	0	
		9	307.9	346.8	0	0	0	0	
		10	311.9	347.9	0	0	0	0	
		11	306.8	346.4	0	0	0	0	-
		12	311.6	351.3	0	0	0	0	
	Control	13	307.1	347.9	0	0	0	0	
	-	14	311.5	356.1	0	0	0	0	
		15	305.9	349.3	0	0	0	0	
		16	301.5	346.6	0	0	0	0	
		17	311.9	351.6	0	0	0	0	
		18	307.3	348.6	0	0	0	0	
		19	306.0	344.4	0	0	0	0	
	Test	20	302.2	340.5	0	0	0	0	0%
	rest	21	307.3	348.1	0	0	0	0	0%
		22	301.9	344.9	0	0	0	0	
SO		23	306.8	346.1	0	0	0	0	
		24	312.0	356.1	0	0	0	0	
		25	307.3	348.3	0	0	0	0	
		26	312.3	355.7	0	0	0	0	
		27	311.6	354.5	0	0	0	0	
	Control	28	309.8	354.0	0	0	0	0	-
		29	306.3	347.9	0	0	0	0	
		30	307.4	345.9	0	0	0	0	

Page 10 of 11

Report No.: CSTBB20030201

			Table 3	Positive	control			
Group	No.	Pretest	Finished			The Chall was rem	Positive	
1000000	20770	weigh(g)	weigh(g)	Erythem	Swelling	Erythem	enge patch swed 48 h Swelling 0 0 0 0 0 0 0 0 0 0 0 0 0	rate
	1	311.2	351.7	2	0	2	0	
	2	315.6	360.2	1	0	1	0	
Test	3	317.2	352.7	0	0	1	0	
	4	312.8	353.9	1.	0	1	0	
	5	306.9	341.1	2	0	2	0	100%
lest	6	312.2	350.6	0	0	1	0	100%
	7	317.1	352.2	1	0	2	0	
	4 5 6 7 8 9	306.8	350.0	1	0	1	0	
	9	316.5	348.7	1	0	2	0	
	10	317.6	350.2	2	0	2	0	
	11	320.5	364.5	0	0	.0	0	
	12	307.6	350.2	0	0	0	0	
Control	13	306.9	345.1	0	0	0	0	-
	14	310.0	352.3	0	0	0	0	
	15	315.8	346.6	0	0	0	0	1

Note: The positive control was CSTBB20010001P1(Finish date: 2020-02-07).









Skin Irritation Test Extraction Method

Final Report

Article Name: Disposable medical face mask

Report Number: CSTBB20030203 Method Standard: ISO 10993-10: 2010

Test Facility

Hunan EEXI Technology&Service

CCIC Huatongwei international inspection (Suzhou) Co., Ltd

Room 101, Building G, Ruoshui Roud 388, Suzhou, Jiangsu, China

CCIC Huatongwei international inspection (Suzhou) Co., Ltd
Address: Room 101, Building G, Russlmi Road 388, Suzhou, Jiangsu, China, 512123 Tel: 0512-87657288 F
Plage 1 of 11 988 Fax: 0512-87657288

Page 11 of 11

CONTENTS

s	3
rct	4
Verification and Signature	5
0 Purpose	6
0 Reference	6
0 Test and control articles.	6
0 Identification of test system	6
0 Animal Managment	7
0 Equipment and reagents	7
0 Experiment design.	7
0 The results observed	
0 Evaluation criteria	9
0.0 Results of the test.	9
.0 Conclusion.	9
.0 Record.	9
3 0 Confidentiality Agreement	9

Page 2 of 11

Abstract

In this study, we took New Zealand white Rabbits to observe the skin irritation of the test article according to ISO10993-10:2010.

The test article were extracted in Constant Temperature Vibrator at 50 °C, 60 rpm for 72 h by 0.9 % Sodium Chloride Injection and Sesame Oil, Apply 0.5 ml extracts of test article or control to 2.5 cm×2.5 cm absorbent gauze patches, and then apply the patch soaked with the extract of test article or control directly to the skin on each side of each rabbin, and then ways the application sites with a bandage for a minimum of 4 h. At the end of the contact time, remove the dressing. The describe and score the skin reaction for crythema and ocdema for each application site at each time interval. Record the appearance of each application site at (± 0.1) h, (24 ± 2) h, (48 ± 2) h and (72 ± 2) h following removal of the patches.

The results showed that the rabbits in the negative control group (0.9 % Sodium Chloride Injection, Sesame Oil) retained a normal appearance throughout the test and showed no skin irritants. A severe skin reactions for erythema and ocdema were shown in the positive control group (SDS). While in test article group, the response of skin on testing side did not exceed that on the control side. The skin reactions for erythema and ocdema were not observed in test article group. The data of each group met the acceptance criteria, and the results of this test were considered valid.

Based on the above results, it can be concluded that under the experimental conditions, the test article Disposable medical face mask has no potential skin irritation on rabbit in the extraction Report No.: CSTBB20030203

Notices

- 1. Please apply for rechecking within 15 days of receiving the report if there is any objection.
 2. Any crasure or without special testing seal renders the report null and void.
 3. The report is only valid when signed by the persons who edited, checked and approved it.
 4. The report is only responsible for the star earlies of the tested samples.
 5. The report shall not be reproduced except in full without the written approval of the company.

Page 3 of 11

Report No: CSTBB20030203

Study Verification and Signature



Protocol Number
Protocol Effective Date SST2003006601BB Technical Initiation Date 2020-03-20 2020-03-27 Technical Completion Date 2020-04-18

Date Completed

Page 5 of 11

Report No.: CSTBB20030203

1.0 Purpose
To evaluate the potential skin irritation caused by test article contact with the skin surface of rabbits and extrapolating the results to humans, but it does not establish the actual risk of irritation.

2.0 Reference

Biological evaluation of medical devices Part 10: Tests for irritation and skin sensitization (ISO 10993-10:

Biological evaluation of medical devices-Part 12: Sample preparation and reference materials (ISO 10993-12:2012)

Biological evaluation of medical devices-Part 2: Animal welfare requirements (ISO 10993-2:2006)

3.0 Test and control articles

Groups	Test article	Negative Control Article(Polar)	Negative Control Article(Non-Polar)	Positive Control
Name	Disposable medical face mask	Sodium Chloride Injection (SC)	Sesame Oil (SO)	10 % sodium dodecy sulfate (SDS)
Hunan EEXI Manufacture Technology&Service Co.,Ltd.		Shijiazhuang No.4 Pharmaceutical	Jiangxi xinsen natural vegetable oil co., Ltd.	SIGMA
Sterilization state	No	1	1	1
Size	17.5cm*9.5cm	500 ml	25 kg	25 g
Model	YX001	1	1	/
Lot Batch#	Not provided	1912121907	181120	SLBL2304V
Test Article Material	PP non-woven, Meltblown filtration layer, earloop and nose clip	,	- 1	7
Physical State	Solid	Liquid	Liquid	Solid
Color	Not provided	Colorless	Light yellow	Colorless
Package material	PE poly bag and paper box	/	1	1
Concentration	-1	0.9%	£	10 %
Total Surface/Weight	Not provided	/	1	7
Storage Condition	Room Tep.	Room Tep.	Room Tep.	Room Tep.


4.0 Identification of test system

Species: New Zealand white Rabbit

Report No.: CSTBB20030203

Use the rabbits with healthy intact skin. Fur was generally clipped within 24 b period before testing on the backs of the rabbits, a sufficient distance on both sides of the spine for application and observation of all test sites (approximately 10-15 cm).

Apply 0.5 ml extract (i) of test article or control to 2.5 cm².2.5 cm absorbent gauze patches, and then apply the patch soaked with the extract of test article or control directly to the skin on each side of each rabbit as shown in Figure 1, and then wrap the application sites with a bundage (semi-exclusive or occlusive) for a minimum of 4h. At the end of the contact time, remove the dressing.



1- Cranial end, 2- Test site, 3- Control site, 4- Clipped dorsal region, 5- Caudal end Figure Location of skin application sites

8.0 The results observed

The Describe and acore the skin reaction for erythema and oedema according to the scoring system given in Table 1 for each application size at each time interval. Record the appearance of each application size at (±0.1) h, (242) h, (4812) h and (72.82) h following removal of the patient.

Erythema and Eschar Formation:	Numerical Grading
No erythema	0
Very slight erythema (barely perceptible)	1
Well-defined erythema	2
Moderate erythema	3
Severe erythema (beet redness) to eschar formation preventing grading of erythema	4
Edema Formation:	
No edema	0
Very slight edema (barely perceptible)	1
Well-defined edema (edges of area well-defined by definite raising)	2
Moderate edema (raised approximately 1mm)	3
Severe edema (raised more than 1mm and extending beyond exposure area)	4
Maximal possible score for irritation	8
Irritation Response Categories in the Rabbit	

Page 8 of 11

Report No.: CSTBB20030203

Report No.: CSTBRO0030201

Number: 6

Sec. 3 § 3, 3 d

Weight: 2.69-2.17 kg

Health status: Bealthy, not previously used in other experimental procedures

Animal identification: Ear status

Cages: Similes seed cage

Accimation Proist. 7 days under the same conditions as for the actual test

42.2 untification of red saystem

The rabbit is specified as an appropriate animal model for evaluating potential skin initiants by the c urrent testing standards. Positive central 10% sodium dosbeeyl sulface has been substantiated at HTW with this method.

50.4 Animal Managment

Animal purchase West length experimental animal breeding on LTD SCXX (SU) 2015-0004

Animal purchase: Wuxi hengtai experimental animal breeding co. LTD SCXK (SU) 2015-0004

Animal purchase: Waxi lengtais experimental animal breeding oo. LTD SCXX (SU) 2015-0004
Bodding: //
Feed: Experimental rabbits were fied a maintenance diet, Woxt hengtai experimental animal breeding oo. LTD
Water: Drinking water met the Standards for Drinking Water Quality GB 5749-2006
Animal room temperature: 18-28 °C.
Animal room returne hunsdigs: 30-97-98
Lights: El bown Fighting, experiment judgeling
Personnel: Associates involved were appropriately qualified and trained
Selection: Only bodding, pervisoraly unsoral animals were selected.
There were no known contaminants present in the feed, water, or bedding expected to interfere with the test

6.0 Equipment and reagents

De Ediphysion and vogene
 All Instruments
 Constant Temperature Vibrator (SHB007, calibration data: 2020/3/16), Autoclave (SHB026, calibration data: 2020/3/16), Electronic scale (SHB017, calibration data: 2020/3/16)

2000/31/6), Electronic scale (STEDUT), CHIPTERING Made According to the following steps:

7.1 Sample preparation

The extracts of test article will be prepared according to the following steps:

Aseptic Sampling				Ext	raction in sterile	vessels	
Sampling Manner	Actually	Ratio	Re	agent	Temperature	Time	pH
Whole	570.2 cm ²	6cm ² : 1 ml	SC	95.0 ml	40.00	22.1	5.5
Whole	570.2 cm ²	ocm: 1 mi	SO	95.0 ml	50 °C	72 h	5.5

The state of the leaching solution and fast echange visually after the leaching was advanced. The extraction and the procession of the control of the control of the leaching was advanced. The extractions were closer, and the pff value has not been adjusted, filtered, centrifuged, diluted and other processes, before doing stored at room temperature no more than 24 h. The control solution was prepared under the same conditions 7.2 Test method

	Report No.: C31BB2005020		
Response Category	Mean score		
Negligible	0 to 0.4		
Slight	0.5 to 1.9		
Moderate	2 to 4.9		
Severe	5 to 8		
9.0 Evaluation criteria			

9.0 Evaluation criteria
Use endy (24:2) h, (48:2) h and (72:2) h observations for calculation.
After the 27 h gading, all cyrthema grades plus ocdems grades (24:2) h, (48:2) h and (72:2) h were localled separately for each test article and blank for each animal. The primary irritation score for an animal was calculated by dividing the sum of all the scores by 6 (two test/observation sites, three time points).
To obtain the primary irritation incides for the test article, add all the primary irritation scores of the individual

animals and divide by the number of animals.

animals and divide by the number of animals.

When blank or negative control was used, calculate the primary irritation score for the controls and subtract that score from the score using the test material to obtain the primary irritation score.

10.0 Results of the test

All animals were survived and no abnormal signs were observed during the study. According to what observed, the response of shin on testing side did not exceed that on the control side. Thus, the primary irritation index for the test article was calculated to be 0. See table 2. The test result showed that the response of the test article extract was categorized as negligible under the test

S THE

12.0 Record

All raw data pertaining to this study and a copy of the final report are retained in designated Huatongwei 13.0 Confidentiality Agreement

Statements of confidentiality were as agreed upon prior to study initiation.

Page 9 of 11

Reagent	Rabbit	Pretest	Finished	Group	Reaction	Inter	val (hours):	score-left	right			
Keagent	No	weigh(g)	weigh(g)	Group	Reaction	Th	24h	48h	72h			
				Test	Erythema	0/0	0/0	0/0	0/0			
	1	2.10	2.18	Article	Oedema	0/0	0/0	0/0	0:0			
	- 1	2.10	2.18	Negative	Erythema	0/0	0/0	0/0	0:0			
				Control	Oedema	0/0	0/0	0/0	0:0			
	Test	Erythema	0/0	0/0	0/0	0:0						
SC	2	2.09	2.16	Article	Oedema	0/0	0/0	0/0	0:0			
SC.	4	2.09	2.10	Negative	Erythema	0/0	0/0	0/0	0:0			
				Control	Oedema	0/0	0/0	0/0	0:0			
				Article	Erythema	0/0	0/0	0/0	0.0			
	3	2.17	2.24		Oedema	0/0	0/0	0/0	0/0			
	3	2.17	2.24		Erythema	0/0	0/0	0/0	0:0			
			1		Oedema	0/0	0/0	0/0	0:0			
Primary irritation index					0							
		4 2.04					Test	Erythema	0/0	0/0	0/0	0/0
	4		2.14	Article	Oedema	0/0	0/0	0/0	0/0			
	4	2.04	2.14	Negative	Erythema	0/0	0/0	0/0	0/0			
				Control	Oedema	0/0	0/0	0/0	0:0			
				Test	Erythema	0/0	0/0	0/0	0/0			
so	5	2.11	2.20	Article	Oedema	0/0	0/0	0/0	0/0			
50	3	2.11	2.20	Negative	Erythema	0/0	0/0	0/0	0:0			
				Control	Oedema	0/0	0/0	0/0	0:0			
				Test	Erythema	0/0	0/0	0/0	0/0			
	6	2.13	2.21	Article	Oedema	0/0	0/0	0/0	0/0			
	.0	2.13	2.21	Negative	Erythema	0/0	0/0	0/0	0:0			
				Control Test Article Negative Control	Oedema	0/0	0/0	0/0	0:0			
		Primary in	ritation index				(

Report No.: CSTBB20030203

Rabbit No.	Group	Reaction	Interva	l (hours): see	we-left site/r	ight site
Rappit No	Group	Reaction	1h	24h	48h	721
	Positive control	Erythema	0./0	1/2	2/3	3/3
1	Positive control	Oedema	0/0	2/1	2/2	3/3
1.	N	Erythema	0/0	0.0	0.0	0.40
	Negative Control	Oedema	0/0	0.0	48h 2/3 2/2 0/0 0/0 3/3 3/3 0/0 0/0 3/3 3/4 0/0 0/0	0./0
	Positive control	Erythema	0/1	2/1	3/3	4/3
2		Oedema	1/0	2/2	3/3	3/4
4		Erythema	0/0	0.0	0.0	0/0
	Negative Control	Oedema	0./0	0.0	2/3 2/2 0/0 0/0 3/3 3/3 0/0 0/0 3/3 3/4 0/0	0./0
	Positive control	Erythema	1/0	1/2	3/3	4/3
200	Positive control	Oedema	0/1	2/1	3/4	3/4
3		Erythema	0/0	0.0	2/3 2/2 0/0 0/0 3/3 3/3 0/0 0/0 3/3 3/4 0/0 0/0	0/0
	Negative Control	Oedema	0/0	0.0	0.0	0/0

Page 10 of 11









In Vitro Cytotoxicity Test

MTT Method

Final Report

Disposable medical face m Report Number: CSTBB20030204

Method Standard: ISO 10993-5: 2009

Hunan EEXI Technology&Service Co.,Ltd.

CCIC Huatongwei international inspection (Suzhou) Co., Ltd
Address Room 101, Building G, Rusoliui Road 388, Suzhau, Liangsu, China, 512123 Tel: 0512-87657288 Fax: 0512-87657288
Päge 1 of 9

CONTENTS Notices Abstract 1.0 Purpose. 2 0 Reference. 3.0 Test and control articles. 4 0 Identification and justification of test system. 5 0 Equipment and reagents. 6.0 Experiment design and dose. 7.0 Statistical method. 8 0 Evaluation criteria. 9 0 Results of the test. 11 0 Conclusion. 11 0 Record.

Page 2 of 9

神

6 もも

- 1. Please apply for rechecking within 15 days of receiving the report if there is any objection.
- Learness apply for feederscange within 15 sups or receiving air export in their is my outpourdine.

 2. Any extractive without special testing seal renders the report null and void.

 3. The report is only valid when signed by the persons who edited, checked and approved it.

 4. The report is only responsible for the test results of the tested samples.

 5. The report shall not be reproduced except in full without the written approval of the company.



Page 3 of 9

Report No.: CSTBB20030204 Study Verification and Signature Protocol Effective Date 2020-03-23 Technical Initiation Date 2020-03-23 2020-03-25 Technical Completion Date Final Report Completion Date 2020-04-18 Date Completed

Abstract

In this study, mammalian L-929 cells were cultured in vitro according to ISO 10993-5:2009 to test the potential cytotoxicity of the test article.

The test articles and the control material were separately placed in MEM medium containing 10% fetal bovine serum, and extracted in a 37 °C incubator for 24 hours. After the end of the extraction, the cell culture medium in the 96-well plate (10* cells/well) cultured for 24 hours was removed and replaced with the corresponding extract, cultured in 3° C, 5% CO₃, 59% CO₃, 59% Co do to 2.4 hours. After the culture, the morphology and cell lysis of the cells were observed under the microscope, and the cytotoxicity of the test samples was determined by MTT assay.

density polyethylene) were well-formed throughout the experiment and showed no cytotoxic reaction. A severe cytotoxic response was shown in the positive control group (ZDEC). The 100% concentration of the test extract retained a normal appearance after 24 hours of incubation, and the cell viability was 78.1%. The data of each group met the acceptance criteria, and the results of this test were valid.

Based on the above results, it can be concluded that under the experimental conditions, the test article Disposable medical face mask have no potential toxicity to L-929 in the MTT method.

Report No.: CSTBB20030204

1.0 Purpose

The purpose of the test is to determine the potential cytotoxicity toxicity of a mammalian cell culture (mouse fibroblast L-929 cells) in response to the test article.

Biological evaluation of medical devices-Part 5: Tests for In Vitro Cytotoxicity (ISO 10993-5; 2009) Biological evaluation of medical devices-Part 12: Sample preparation and reference materials (ISO 10993-12:

Groups	Test article	Negative Control Article	Positive Control Article	Blank Control MEM medium, with addition 10% FBS	
Name	Disposable medical face mask	High Density Polyethylene Film	ZDEC		
Manufacture	Hunan EEXI Technology&Service Co.,Ltd.	Hatano Research Institute. FDSC	Sigma-Aldrich.	Hyclone	
Size	17.5cm*9.5cm	3 cm×10 cm (5 sheets)	25 g	500 ml	
Model	YX001	1	7	7	
Lot Batch#	Not provided	C-161	BCBQ6847V	AE29441978	
Test Article Material	PP non-woven, Meltblown filtration layer, earloop and nose clip	-1-	1	7 · c	
Physical State	Solid	Solid	Solid	Liquid	
Color	Not provided	White	White	Pink	
Packaging Material	PE poly bag and paper box	1	./	7.	
Sterilized or Not	No	No	No	Yes	
Concentration	1	1	0.1%	7.	
Total Surface	Not provided	1	7	T	
Storage Condition	Room Tep.	Room Tep.	Room Tep.	4°C	

Note: The information about the lest article was supposed by the aponsor wherever application.

4.0 Identification and justification of test system.

L-929 mouse fibroblast cells obstanted from American Type Culture Collection (ATCC).

L-929 cells have been used for cystocicity andies because they demonstrate sensitivity to extractable systems criticles. Also, the test article is extracted and administered in vitro to mouse fibroblast Jc29 cells through a solvent compatible with the test system, which is the optimal route of administration available in this test system as recommended in ISO 10993-5.

Page 6 of 9

5.1 Instruments.
Vertical pressure steam sterillzer (SHB026), CO; Incubator (SHB002), Seed Straight Scale (SHB076), Electronic Ballance (SHB016), Clean bench (SHB014), Multislans Spectrum Microplate Spectrophotometer (SHB002), Bench type low speed centrifuge (SHB022), Inverted microscope (SHB005)

MEM (Hyclone, AE2944)978), FBS (Clark, JC65116), Penicillin-Streptomycin (Gibco, 2145453), Trypsi n (Gibco, 2048080), PBS (Hyclone, AE29451445), MTT (3-44,5-Dimethylthiazol-2-yl)-2,5-diphenyletrazolium bromide) (Sigma, MKBG2038V), Isopropyl alcoho (Marklin, C10394867)

for Experiment design and dose
6.1 Sample preparation
According to the table below, as experimental article scaled and incubated in MEM medium (10%
FBS) at 37 °C, 5% CO₂ and 60 pm for 24 hours.

Groups		oling Sterilization		Aseptic Extraction In Inert Container				
Groups	Sampling Manner	Actually sampling	Method	Ratio	Extracts	Condition	pН	Clear or Not
Test article	Whole	570.2 cm ²	EO	6 cm ² : 1 ml	95.0 ml	37 ℃ 24 h	7.4	Clear
Negative Control	Random	60 cm ²	UV	3 cm ² : 1 ml	20.0 ml	37 °C 24 h	7.4	Clear
Positive Control	Random	0.02 g	Filter	0.1 g; 100 ml	20.0 ml	37 ℃ 24 h	7.4	Clear
Blank Control	7	¥	F	1	10.0 ml	37 ℃ 24 h	7.4	Clear

Blank
Control
The changes of the leaching solution was observed after extraction. No particulates or color changes were observed in general potential control of the changes of the leaching solution was observed after extraction. No particulates or color changes were observed in gree and postertarction, and immediately be used in the follow-up experiment. The color and gel of the extraction solution tild not change before and after use, and the pH value was 7.4 after teaching.
6.2 Test method
Asspire procedures were used for handling cell cultures. L-929 cells were cultured in MEM mediam (10%-FIBS, 11% Penscillan-Streptunoysin solution) at 37°C in a hamidided atmosphere of 5% CO₂, then digested by 0.25% tryption containing EUTA to get single cell suspension. L 1×0° cellulor suspension were obtained by centrifuging (1000 typn, 5 min) and re-dispersing in MEM mediam.

The suspended cells were dispensed at 100 pl per well in 86 well plate, and cultured in cell incubator (5% CO₂, 57°C, -90%); hamily, Cell suspelpoley was estimated to verify that the monolayer was satisfactory.

After the cells gree to about 70% and form a monolayor, original culture mediam was discarded. The 96-well plates were then treated with 100 pl a ferrant of rest article (10%). 75% is 50%, 25%, counted article, negative article and positive article respectively. The 96-well plate was incubated at 37°C in cell incubator of 5% CO₂ for 24 b. Six replicates of each test were tested.

Page 7 of 9

Report No.: CSTBB20030204

	cell lysis and slight growth inhibition.
	The cells showed a round shape and a change
25% Test article	in cell morphology occasionally, and there
extract	were particles in the cytoplasm, occasionally
	cell lysis and slight growth inhibition.

9.2 Results of the cell vitality

Table2 Results of the cell vitality

Group	OD value								
	1	2	3	4	5	6	x	s	Viab. (%
Blank control	0.601	0.663	0.638	0.655	0.606	0.629	0.632	0.025	100.0
Negative control	0.598	0.582	0.598	0.599	0.597	0.593	0.595	0.006	94.1
Positive control	0.054	0.062	0.061	0.059	0.068	0.064	0.061	0.005	9.7
100% test article extract	0.489	0.497	0.486	0.495	0.492	0.502	0.494	0.006	78.1
75% test article extract	0.523	0.525	0.535	0.524	0.519	0.508	0.522	0.009	82.6
50% test article extract	0.539	0.538	0.547	0.536	0.535	0.537	0.539	0.004	85.2
25% test article extract	0.549	0.555	0.567	0.589	0.585	0.565	0.568	0.016	89.9

Under the conditions of this study, the test article have no potential toxicity to L-929 cells.

11.0 Record

All raw data pertaining to this study and a copy of the final report are to be stored in the designated archive s at Hustongwei.

files at Huatongwei. 12.0 Confidentiality Agreement

Statements of confidentiality were as agreed upon prior to study initiation.

Page 9 of 9

Report No.: CSTBB20030204

Report No. CSTBB20030204
After incubation, observe the cell morphology first and then discard the culture medium. Add 50 µ MTI
(Imgrill) to each well and then incubated at 37 °C in a himstified atmosphere of 5% (Co) for 2 hours. The liquid in each well was tipped out and 100 µ I sopropyl alcolo was added to each well to suspend the cell layer.

Evaluate the suspension above with a dual-wavelength spectrophotometer with the measurement wavelength at 570 mm.

7.0 Statistical method

Meanistandard deviation (\bar{x} ±a)

The cell cytotoxicity ratio = OD₂₉₀ of test (or positive or negative) article group OD₂₉₀ of blank control

8.0 Evaluation criteria

- 8.0 Evaluation criteria
 8.1 The 50% extract of the test article should have at least the same or a higher viability than the 100% extract.
 Otherwise the test should be repeated.
 8.2 The lower the Vish 5's value, the higher the cytotoxic potential of the test article is.
 8.3 Twishility is reduced to < 70% of the blank, it has a cytotoxic potential.
 8.4 The Vish 5's of the 100% extract of the test article is the final result.
 9.0 Results of the test
 9.1 Results of the cell morphology
 Table 1 Observation of the cell morphology

11

Group	Before inoculation	Before treated with extract	24 h after treatment
Blank control	14 1		Discrete intracytoplasmatic granules, no cell lysis, no reduction of cell growth.
Negative control			Discrete intracytoplasmatic granules, no cell lysis, no reduction of cell growth.
Positive control	Discrete intracytoplasmatic granules, no cell lysis, no reduction of cell growth.	Discrete intracytoplasmatic granules, no cell lysis, no reduction	Nearly complete or complete destruction of the cell layers.
100% Test article extract			The cells showed a round shape and a change in cell morphology occasionally, and there were particles in the cytoplasm, occasionally cell lysis and slight growth inhibition.
75% Test article extract		of cell growth.	The cells showed a round shape and a change in cell morphology occasionally, and there were particles in the cytoplasm, occasionally cell lysis and slight growth inhibition.
50% Test article extract			The cells showed a round shape and a change in cell morphology occasionally, and there were particles in the cytoplasm, occasionally





中华人民共和国医疗器械注册证

注册证编号:湘械注准20202140297

注册人名称	湖南一喜科技服务有限公司
注册人住所	湖南湖阳高新技术产业开发区坪头北路6号3栋
生产地址	湖南浏阳高新技术产业开发区坪头北路6号3栋
代理人名称	不适用
代理人住所	不适用
产品名称	一次性使用医用口罩(非无菌型)
型号、规格	产品按照面罩形状分为平面形(PM),按照佩戴方式可以分为耳挂式 (G)、佛带式(B) 威头带(D)式,按照尺寸可以分为A、B、C、D、 E、F、G-七种规格。
结构及组成	本产品由聚布、募夹、口罩带组成、聚布内外层由无纺布,中间层由 熔喷布制成,口罩带由非织造布或松紧带制成, 募夹由可弯折的聚丙 烯鼻夹材料制成,该产品非无菌供应。
适用范围	适用于佩戴者在无在体液和喷溅风险的普通医疗环境下的卫生护 理。
附件	产品技术要求
其他内容	
备 注	 该产品为应急审批注册。有效期为八个月,2.该产品在延续/变更》 册时应按医疗器械注册管理要求完善相关资料。

审批部门:湖南省药品监督管理局















证书号: USA20E40925R0M

兹证明

湖南一喜科技服务有限公司

统一社会信用代码: 91430181MA4PHUE510

注册地址:湖南浏阳高新技术产业开发区坪头北路6号 生产地址:湖南浏阳高新技术产业开发区坪头北路6号3栋一、二楼 办公地址:湖南浏阳高新技术产业开发区坪头北路6号办公楼

环境管理体系符合标准

ISO 14001:2015 环境管理体系适用范围

一次性使用医用口罩(非无菌型)、一次性使用医用口罩(无菌型)、医用外科口罩 (非无菌型)、医用外科口罩(无菌型)的生产(该公司许可证范围内) 及其所涉及场所的相关环境管理活动

初次发证日期 2020年04月20日 证书颁发日期 2020年04月20日 证书统发日期 2020年05月12日 证书统发日期 2020年05月12日









Certificate No.: USA20E40925R0M

This is to certify that the Environmental Management System of

HUNAN EEXI TECHNOLOGY & SERVICE CO., LTD.

Unified Social Credit Code: 91430181MA4PHUE510

Unified Social Credit Code; 91430181MA4PHUE510
Registered/Office Address: No.6 North of Pingtou Road, Liuyang Hi-Tech Industrial
Development Zone, Hunan, China
Production Address: Floor 1 and 2, Building 3, No.6 North of Pingtou Road, Liuyang Hi-Tech
Industrial Development Zone, Hunan, China

Has been audited to conform to the following Environmental Management System standard

ISO 14001:2015

TISO 14001:2015

This Environmental Management System is valid for the
The production of disposable medical masks (non-sterile), disposable medical masks (sterile), medical surgical masks (non-sterile) and medical surgical masks (sterile) (within the company's license scope) and related environmental management activities of involved sites

Date of initial issuance: Apr. 20, 2020 Date of issuance: Apr. 20, 2020 Date of renewal: May. 12, 2020 Date of expiry: Apr. 19, 2023

Issued by: We Forgre Beijing East Al







